Loading…
Arcus Biosciences, Inc. is projected to rise to $35.18 by 2027, a +25% move from its current price of $28.25. RCUS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $27.43 | $28.25 | $29.09 | -0.01% |
| Aug 2 | $27.09 | $28.24 | $29.44 | -0.03% |
| Aug 3 | $26.83 | $28.24 | $29.72 | -0.04% |
| Aug 4 | $26.62 | $28.23 | $29.95 | -0.06% |
| Aug 5 | $26.43 | $28.23 | $30.15 | -0.07% |
| Aug 6 | $26.26 | $28.23 | $30.34 | -0.09% |
| Aug 7 | $26.10 | $28.22 | $30.51 | -0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.10 | $28.22 | $30.51 | -0.10% |
| Week 2 | $25.25 | $28.19 | $31.48 | -0.21% |
| Week 3 | $24.60 | $28.16 | $32.24 | -0.31% |
| Week 4 | $24.07 | $28.13 | $32.88 | -0.41% |
| Week 5 | $23.61 | $28.11 | $33.46 | -0.51% |
| Week 6 | $23.19 | $28.08 | $33.99 | -0.62% |
| Week 7 | $22.82 | $28.05 | $34.48 | -0.72% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes cancer therapies in the United States. Its development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
The company also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, it develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. Arcus has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P.
to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer.
Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Arcus Biosciences, Inc. (RCUS) is a healthcare company currently priced at $28.02 with a market capitalization of $3.52B and a rank of 1650. The stock trades within a broad context of long-term growth expectations reflected in the 2026–2050 forecast data.
For 2026, the avg price is $28.02 with a min of $18.85 and a max of $36.11, and a neutral sentiment. This year anchors the near-term outlook to a baseline that mirrors the current price level.
From 2027 onward, the forecast shows a rising price trajectory with bullish sentiment. The avg price progresses to $35.36 in 2027, $42.21 in 2028, $54.68 in 2029, and $67.53 in 2030, with continued increases through 2031–2050. By 2050, the avg forecast reaches $444.32, accompanied by a high ROI figure of 1485.7%.
Overall, the long-run outlook points to substantial price appreciation across the forecast horizon, with sentiment turning bullish in the later years and notable upside potential reflected in the multi-decade targets.
A major floor 28.3% below — a decisive break under it would weaken the trend.
The nearest floor, 14.6% below — buyers have tended to step in here.
The nearest ceiling, 10.0% above — a clean break opens room to run.
A major ceiling 23.1% above — clearing it would confirm fresh momentum.
Key RCUS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RCUS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $27.60 | Buy | $27.77 | Buy |
| MA 10 | $28.27 | Sell | $28.06 | Buy |
| MA 20 | $28.67 | Sell | $28.14 | Buy |
| MA 50 | $26.71 | Buy | $27.12 | Buy |
| MA 100 | $25.10 | Buy | $25.47 | Buy |
| MA 200 | $23.22 | Buy | $22.79 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.35 | Neutral |
| Stoch RSI (14) | 51.34 | Neutral |
| CCI (20) | -26.18 | Neutral |
| Williams %R (14) | -48.86 | Info |
| MACD (12,26,9) | -0.31 | Sell |
| ROC (12) | -0.28 | Sell |
| Bollinger %B (20,2) | 0.41 | Neutral |
| Stochastic %K (14) | 51.14 | Neutral |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | -0.43 | Sell |
| Ultimate (7,14,28) | 44.30 | Neutral |
| Momentum (10) | 1.61 | Buy |
| Aroon Osc (25) | -84.00 | Sell |
| Hull MA (9) | 26.70 | Buy |
| ADX (14) | 13.90 | Neutral |
| ATR (14) | 0.81 | Info |
The near-term technical picture shows a 30-day range of $23.29 to $33.72, highlighting a relatively wide trading band around the current price.
RSI(14) is 50, with the 50-day simple moving average at $26.03 and the 200-day simple moving average at $22.44, suggesting a convergence near key moving averages. Support is noted at $22.12 and resistance at $31.08, indicating potential congestion around the mid-$20s to low-$30s area.
Overall near-term sentiment is bullish, with the price hovering around the mid-range of its recent trajectory and a defined set of moving averages and support/resistance levels guiding short-term moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $18.85 | $28.25 | $36.67 | 0% | Neutral | |
| $27.85 | $35.18 | $47.11 | +25% | Bullish | |
| $32.51 | $42.35 | $59.03 | +50% | Bullish | |
| $42.36 | $56.59 | $81.38 | +100% | Bullish | |
| $49.81 | $68.07 | $100.46 | +141% | Bullish | |
| $56.43 | $78.71 | $118.83 | +179% | Bullish | |
| $62.61 | $89.01 | $137.15 | +215% | Bullish | |
| $61.36 | $88.81 | $139.36 | +214% | Bullish | |
| $69.50 | $102.31 | $163.29 | +262% | Bullish | |
| $82.60 | $123.61 | $200.38 | +338% | Bullish | |
| $130.23 | $209.92 | $363.28 | +643% | Bullish | |
| $257.72 | $472.72 | $899.33 | +15.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $18.85 | $28.25 | $32.99 | +0.00% |
| August 2026 | $24.39 | $28.67 | $34.53 | +1.50% |
| September 2026 | $23.50 | $27.87 | $34.06 | -2.79% |
| October 2026 | $23.29 | $27.82 | $34.38 | -0.18% |
| November 2026 | $24.06 | $28.92 | $36.07 | +3.94% |
| December 2026 | $24.13 | $29.16 | $36.67 | +0.82% |
Click any year to see its month-by-month RCUS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Arcus Biosciences, Inc.'s 2026 outlook centres on $28.25, within a $18.85 to $36.67 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, RCUS could reach as high as $47.11, with a base case around $35.18 and support toward $27.85 — roughly +25% from $28.25. Buyers look set to stay in control over this stretch.
Expect RCUS to range from $32.51 to $59.03 through 2028. The $42.35 average target implies a +50% move from current prices. That is up +20% on the projected 2027 average. Momentum favours further upside here.
The RCUS price prediction for 2029 points to an average of $56.59 (low $42.36, high $81.38) — a potential gain of +100% on today's $28.25. Buyers look set to stay in control over this stretch.
In 2030, RCUS is projected to trade between $49.81 and $100.46, averaging $68.07 — a potential gain of +141% from today's $28.25. That is up +20% on the projected 2029 average. Momentum favours further upside here.
Arcus Biosciences, Inc.'s 2031 outlook centres on $78.71, within a $56.43 to $118.83 range. That is up +16% on the projected 2030 average. That marks a +179% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, RCUS could reach as high as $137.15, with a base case around $89.01 and support toward $62.61 — roughly +215% from $28.25. Momentum favours further upside here.
Expect RCUS to range from $61.36 to $139.36 through 2033. The $88.81 average target implies a +214% move from current prices. That is 0% versus the projected 2032 average. Buyers look set to stay in control over this stretch.
The RCUS price prediction for 2034 points to an average of $102.31 (low $69.50, high $163.29) — a potential gain of +262% on today's $28.25. Momentum favours further upside here.
In 2035, RCUS is projected to trade between $82.60 and $200.38, averaging $123.61 — a potential gain of +338% from today's $28.25. That is up +21% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Arcus Biosciences, Inc.'s 2040 outlook centres on $209.92, within a $130.23 to $363.28 range. That is up +70% on the projected 2035 average. That marks a +643% change versus current levels. Momentum favours further upside here.
By 2050, RCUS could reach as high as $899.33, with a base case around $472.72 and support toward $257.72 — roughly +15.7x from $28.25. Buyers look set to stay in control over this stretch.
Investing $1,000 in RCUS today (≈ 35.39823 RCUS) could be worth
$16,733.48
+$15,733.48 (+1573%) by 2050 · US Dollar
Based on the average projected RCUS price of $472.72 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RCUSwould be worth at today's price.
$1,000 invested in RCUS on Jul 30, 2025 (≈ 106.044535 RCUS) would be worth
$2,995.76
+$1,995.76 (+199.6%) today · 3.00× · US Dollar
Based on a RCUS entry price of $9.43 vs. today's $28.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $29.73 | $950.22 | -5.0% |
| 1 month ago | $30.83 | $916.32 | -8.4% |
| 3 months ago | $25.68 | $1,100.08 | +10.0% |
| 6 months ago | $21.04 | $1,342.68 | +34.3% |
| 1 year ago | $9.43 | $2,995.76 | +199.6% |
| All time (5.0y) ago | $30.05 | $940.1 | -6.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RCUS forecast.
Our base-case forecast reaches $57.00 around 2030.
Implied market cap at $57.00: $7.17B
The multi-year forecast lays out a path of substantial price growth with specific year-by-year averages and ROI figures. The 2027 avg is $35.36 with ROI 26.2 and bullish sentiment, followed by 2028 avg $42.21 (ROI 50.6) and 2029 avg $54.68 (ROI 95.2).
In 2030 the avg reaches $67.53 (ROI 141) with bullish sentiment, then 2031 at $76.99 (ROI 174.8) and 2032 at $84.61 (ROI 202). The 2033 avg is $87.65 (ROI 212.8) and 2034 avg $100.30 (ROI 257.9). By 2035 the avg is $118.12 (ROI 321.6), and the trajectory remains bullish through 2040 at $200.50 (ROI 615.6) and 2050 at $444.32 (ROI 1485.7).
These are estimates, not guarantees, and they reflect a continuing bullish outlook over the long term with notable upside potential and associated uncertainty.
Tap a question to reveal the answer.
The 2030 forecast gives an avg price of $67.53, with a min of $49.82 and a max of $98.74, and a ROI of 141. The sentiment is BULLISH.
Forecasts show a path of rising averages from 2027 onward with a bullish sentiment and a 2030 avg of $67.53 (ROI 141) and a 2050 avg of $444.32 (ROI 1485.7). Note that 2026 is neutral with an avg of $28.02 and ROI 0.
Yes. The 2034 forecast lists a min of $68.99, an avg of $100.30, and a max of $158.09, with a ROI of 257.9 and a BULLISH sentiment.
Current price is $28.02 and market cap is $3.52B, with a rank of 1650.
The 30-day range is $23.29 to $33.72. The RSI(14) is 50, SMA(50) is $26.03, SMA(200) is $22.44, with support at $22.12 and resistance at $31.08. The near-term sentiment is BULLISH.
Arcus Biosciences, Inc. Community Discussion
0Share your Arcus Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.